<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29742702</article-id><article-id pub-id-type="pmc">5959386</article-id><article-id pub-id-type="publisher-id">MD-D-18-01656</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000010636</article-id><article-id pub-id-type="art-access-id">00636</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>3800</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial/Experimental Study</subject></subj-group></article-categories><title-group><article-title>Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease</article-title><subtitle>A pilot study</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Guo-hui</given-names></name><degrees>MM</degrees></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Li-hua</given-names></name><degrees>MM</degrees></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chen</given-names></name><degrees>MM</degrees></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Li-hong</given-names></name><degrees>MD</degrees><xref rid="cor1" ref-type="corresp"><sup>&#x02217;</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Zhang.</surname><given-names>Qinhong</given-names></name></contrib></contrib-group><aff>Department of Neurology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.</aff><author-notes id="cor1"><corresp><label>&#x02217;</label>Correspondence: Li-hong Qin, First Ward of Neurology Department, First Affiliated Hospital of Jiamusi University, No. 348 Dexiang Street, Xiangyang District, Jiamusi 154003, China (e-mail: <email>lihongq112@163.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>11</day><month>5</month><year>2018</year></pub-date><volume>97</volume><issue>19</issue><elocation-id>e0636</elocation-id><history><date date-type="received"><day>8</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-97-e0636.pdf"/><abstract><title>Abstract</title><sec sec-type="background"><title>Background:</title><p>This study explored the feasible efficacy and safety of the Spore Powder of Ganoderma Lucidum (SPGL) for treating patients with Alzheimer disease (AD).</p></sec><sec sec-type="methods"><title>Methods:</title><p>Forty-two eligible patients with AD were recruited. These patients were randomly allocated to an intervention group and a control group equally. The patients in the intervention group underwent SPGL, whereas the subjects in the control received placebo. All patients were treated for a total of 6 weeks. The primary outcome was measured by Alzheimer's disease Assessment Scale-Cognitive (ADAS-cog). The secondary outcomes were measured by the World Health Organization Quality of Life questionnaire (WHOQOL-BREF) and Neuropsychiatric Index (NPI). The adverse events were also recorded during the treatment period.</p></sec><sec sec-type="results"><title>Results:</title><p>At the end of the treatment, GLSP did not show more encouraging outcomes in symptoms improvement, measured by the ADAS-cog (<italic>P</italic>&#x0200a;=&#x0200a;.31), and NPI (<italic>P</italic>&#x0200a;=&#x0200a;.79); and quality of life enhancement, measured by the WHOQOL-BREF (physical, <italic>P</italic>&#x0200a;=&#x0200a;.62; psychological, <italic>P</italic>&#x0200a;=&#x0200a;.69; social relationships, <italic>P</italic>&#x0200a;=&#x0200a;.75; environment, <italic>P</italic>&#x0200a;=&#x0200a;.82; overall quality of life, <italic>P</italic>&#x0200a;=&#x0200a;.74), compared with the control group. In addition, all adverse events were mild, and no significant differences were found between 2 groups.</p></sec><sec sec-type="conclusion"><title>Conclusion:</title><p>The results of this study did not find the promising efficacy of SPGL for the treatment of AD after 6-week treatment. It may be because of the relative short-term of intervention. Future clinical trials with larger sample size and longer treatment period are urgently needed.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Alzheimer disease</kwd><kwd>Spore Powder of Ganoderma Lucidum</kwd><kwd>efficacy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>Alzheimer disease (AD) is a chronic progressive neurodegenerative disease among elderly population.<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]</sup> It often manifests with losing of reasoning, memory, language, and personality changes.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> It has been reported that AD accounts for 60% to 70% of all dementia cases.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> It has been estimated that the worldwide prevalence increases from 26.6 million in 2006 to the quadruple numbers with 1 in 85 persons worldwide by 2050.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> The health care costs $172 billion per year for patients with AD in the United States alone.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> Thus, it brings a severer public health challenge for the society, especially with the rapid increase of the aging population worldwide.</p><p>Treatment mainly consists of cognition enhancing medications. These medications include donepezil,<sup>[<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]</sup> galantamine,<sup>[<xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>]</sup> memantine,<sup>[<xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref>]</sup> and rivastigmine.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> However, all these medications can not cure AD completely. They just temporarily relieve symptoms, such as mental function, lowers blood pressure, and balance mood for patients with AD.<sup>[<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R18" ref-type="bibr">18</xref>]</sup> Most importantly, if patients received these medications for a long term, they also bring lots of adverse events for the patients.<sup>[<xref rid="R19" ref-type="bibr">19</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref>]</sup></p><p>Alternative treatment is urgently for patients with AD. Spore Powder of Ganoderma Lucidum (SPGL) is a potential intriguing candidate. Animal studies have support the efficacy of SPGL for the treatment of AD.<sup>[<xref rid="R22" ref-type="bibr">22</xref>&#x02013;<xref rid="R29" ref-type="bibr">29</xref>]</sup> However, there is still no clinical study that investigates the efficacy and safety of SPGL for treating patients with AD. In this pilot study, we evaluated the feasible efficacy and safety of SPGL in Chinese patients with AD.</p></sec><sec><label>2</label><title>Methods/design</title><sec><label>2.1</label><title>Objective</title><p>The primary objective of this pilot study is to evaluate the feasible efficacy of SPGL for treating patients with AD.</p></sec><sec><label>2.2</label><title>Design</title><p>This pilot-randomized controlled trial included a 6-week treatment period. Forty-two eligible patients with AD were equally and randomly allocated to an intervention group and a control group. After randomization, patients in the intervention group underwent SPGL, whereas patients in the control group received placebo over a period of 6 weeks. All outcomes were measured and evaluated at baseline and at the end of 6-week treatment.</p><p>This clinical study was conducted based on the principles of the Declaration of Helsinki (version Seoul, 2008). It was approved by the Ethical Committee of First Affiliated Hospital of Jiamusi University. It was conducted at the same hospital from January 2016 to December 2017. All patients provided written informed consent.</p></sec><sec><label>2.3</label><title>Participants</title><p>Patients were recruited through advertisements and posted notices. The recruitment period was from January 2016 to December 2017. The study inclusion criteria of patients were as follows: confirmed diagnosed as AD according to the criteria of Diagnostic and Statistical Manual of Mental Disorders<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup>; age between 50 to 86 years; a Minimental State Examination (MMSE) score: 10&#x02264;MMSE&#x02264;23,<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> and a Hamilton depression scale(HAMD) score: HAMD &#x0003c;7. Patients were excluded if they had asthma or chronic obstructive pulmonary disease; alcohol or drugs abuse; abnormal functions of liver and kidney; psychiatric or severe neurologic diseases, such as brain cancer; and medications to improve the cognitive function during the past 1 month before the recruitment of this study. In addition, patients were also excluded if they had received SPGL within 1 month before the study.</p></sec><sec><label>2.4</label><title>Randomization allocations and blinding</title><p>After the baseline evaluation, all eligible patients with AD were randomly allocated into either an intervention group or a control group in a ratio of 1:1. The randomization was conducted by a professional statistician using SPSS Statistics 17.0 (IBM Corp., Armonk, NY) with computer-generated, randomly location. After randomization, the random number table was sealed in an opaque envelope. All patients, researchers, outcome assessors, and data analysts were masked to the allocation of this study.</p></sec><sec><label>2.5</label><title>Intervention schedule</title><p>All patients in the intervention group received SPGL (Provided by Beijing Great Wall Pharmaceutical Factory with Batch number of B20050008), 4 capsules of 1000&#x0200a;mg each time (250&#x0200a;mg/capsule), 3 times daily, and 7 days weekly for a total of 6 weeks. The patients in the control group received placebo, the same dose, size, color, flavor as the SPGL, as well as the same provider.</p></sec><sec><label>2.6</label><title>Outcome measurements</title><p>The primary outcome was measured by Alzheimer's disease Assessment Scale-Cognitive (ADAS-cog). This tool covers 11 items to evaluate the multiple cognitive domains, including memory, language, praxis, and orientation. It varies from 0 to 70. The higher scores indicate the greater impairment. The secondary outcomes were measured by the World Health Organization Quality of Life questionnaire (WHOQOL-BREF)<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> and Neuropsychiatric Index (NPI).<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> WHOQOL-BREF was used to assess the quality of life.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> It consists of the domains of physical, psychological, social relationships, environment, and overall quality of life, with the higher scores indicating the greater quality of life. NPI scale was to evaluate the frequency and severity of behavioral symptoms.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> It includes 10 neuropsychic symptoms and 2 autonomic nervous symptoms. The scores range from 0 to 144, with the higher scores indicating severer behavioral disturbance.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> The adverse events were also documented during the treatment period.</p></sec><sec><label>2.7</label><title>Sample size</title><p>This study is a pilot study for the assessment of GLSP for patients with AD and the feasibility of a further larger clinical trial. The desired sample size of this pilot study is 42 patients because of the short duration with 6 weeks. Each group had 21 patients with 15% dropout rate, which is the minimum sample size necessary to assess the efficacy of GLSP for AD.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup></p></sec><sec><label>2.8</label><title>Statistical analysis</title><p>All variables were analyzed by using SPSS Statistics 17.0 (IBM Corp., Armonk, NY). Chi-square test was used to analyze the count data. Student <italic>t</italic> test was used to analyze measurable data. All the outcome data were analyzed based on the intent-to-treat principle. All safety related data were summarized by using the descriptions if there were not significant differences between the 2 groups after the treatment. <italic>P</italic> &#x0003c; .05 was considered as the statistical significance.</p></sec></sec><sec><label>3</label><title>Results</title><p>In this pilot study, 71 patients were recruited for eligibility assessment initially (Fig. <xref ref-type="fig" rid="F1">1</xref>). Of these patients, 29 were excluded because they did not meet the inclusion and exclusion criteria. The remaining 42 patients equally assigned to the intervention group and the control group. All patients in both groups completed the treatment.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flowchart of patient selection.</p></caption><graphic xlink:href="medi-97-e0636-g001"/></fig><p>The characteristics of all included patients at baseline are listed in Table <xref ref-type="table" rid="T1">1</xref>. There were not significant differences of all patients&#x02019; characteristics between 2 groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of included patients.</p></caption><graphic xlink:href="medi-97-e0636-g002"/></table-wrap><p>At the end of the treatment, patients in the intervention group did not achieve better symptoms improvements, measured by the ADAS-cog (<italic>P</italic>&#x0200a;=&#x0200a;.31; Table <xref ref-type="table" rid="T2">2</xref>), and NPI (<italic>P</italic>&#x0200a;=&#x0200a;.79; Table <xref ref-type="table" rid="T3">3</xref>), compared with those patients in the control group. In addition, patients in the intervention group also did not enhance their quality of life more than patients in the control group, measured by the WHOQOL-BREF (physical, <italic>P</italic>&#x0200a;=&#x0200a;.62; psychological, <italic>P</italic>&#x0200a;=&#x0200a;.69; social relationships, <italic>P</italic>&#x0200a;=&#x0200a;.75; environment, <italic>P</italic>&#x0200a;=&#x0200a;.82; overall quality of life, <italic>P</italic>&#x0200a;=&#x0200a;.74; Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Primary outcome measurements at the end of the 6-week treatment (change from baseline).</p></caption><graphic xlink:href="medi-97-e0636-g003"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Secondary outcome measurements at the end of the 6-week treatment (change from baseline).</p></caption><graphic xlink:href="medi-97-e0636-g004"/></table-wrap><p>All adverse events related to the treatment are showed in Table <xref ref-type="table" rid="T4">4</xref>. No significant differences of adverse events were found between 2 groups. All adverse events were mild, and no severe adverse events occurred.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Adverse events occurred between 2 groups.</p></caption><graphic xlink:href="medi-97-e0636-g005"/></table-wrap></sec><sec><label>4</label><title>Discussion</title><p>Previous related animal studies found that Ganoderma lucidum polysacchraride peptide (GLPP) can make the senile plaques and neurofibrillary degeneration in the brain, and reduce amyloid vascular lesions.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> It has been reported that GLPP can also decrease the levels of A&#x003b2;, 3,4-methylenedioxyamphetamine,<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> and synaptophysin/synapse, reducing the expression of FasL and caspase-3 in hippocampus, inhibiting tau hyperphosphorylation, alleviating the ultrastructure damage and improving the spatial memory ability of rats with AD.<sup>[<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R25" ref-type="bibr">25</xref>&#x02013;<xref rid="R26" ref-type="bibr">26</xref>]</sup> Moreover, GLPP can enhance the learning and memory ability and antioxidant capacity in the A&#x003b2;-induced AD model rats,<sup>[<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R28" ref-type="bibr">28</xref>]</sup> and improve neuronal degeneration in the hippocampal CA1 area.<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R28" ref-type="bibr">28</xref>]</sup> The other study has also reported that GLPP has certain protective effect on hippocampal degenerative neurons induced by A&#x003b2;25 to 35 in rat model of AD and can also reduce neuroinflammation in brain tissue.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> However, no clinical study of GLSP for treating AD has been reported.</p><p>To our best knowledge, this pilot clinical trial first explored the feasible efficacy and safety of SPGL for the treatment of patients with AD. The results did not show encouraging efficacy of SPGL in ADAS-cog, WHOQOL-BREF, and NPI, when compared with the placebo. It may be because of the relative short period of GLSP therapy. Within such 6-week treatment, GLSP may start to work, but it still did not achieve the statistical significance.</p><p>This pilot study has several limitations. First, this study is a pilot study, and it just assesses the feasible efficacy and safety of SPGL for treating patients with AD. Then, it has a pretty small sample size. Finally, this study only included 6-week period of treatment. Thus, all those limitations may affect the results of this study.</p></sec><sec><label>5</label><title>Conclusion</title><p>The results of this study demonstrated that SPGL may not benefit to patients with AD after 6-week treatment. It may be because of the too short treatment period. Thus, further studies should extend the treatment duration, as well as enlarge the sample sizes of the patients with AD.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Li-hong Qin, Guo-hui Wang.</p><p><bold>Data curation:</bold> Li-hong Qin, Guo-hui Wang.</p><p><bold>Formal analysis:</bold> Guo-hui Wang.</p><p><bold>Investigation:</bold> Guo-hui Wang.</p><p><bold>Methodology:</bold> Chen Wang.</p><p><bold>Project administration:</bold> Li-hong Qin, Chen Wang.</p><p><bold>Resources:</bold> Li-hua Wang.</p><p><bold>Software:</bold> Li-hong Qin, Li-hua Wang, Chen Wang.</p><p><bold>Supervision:</bold> Chen Wang.</p><p><bold>Validation:</bold> Li-hua Wang.</p><p><bold>Visualization:</bold> Li-hua Wang, Chen Wang.</p><p><bold>Writing &#x02013; original draft:</bold> Li-hong Qin, Guo-hui Wang, Li-hua Wang, Chen Wang.</p><p><bold>Writing &#x02013; review and editing:</bold> Li-hong Qin, Guo-hui Wang, Li-hua Wang, Chen Wang.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: AD = Alzheimer disease, ADAS-cog = Alzheimer's disease Assessment Scale-Cognitive, GLPP = Ganoderma lucidum polysacchraride peptide, HAMD = Hamilton depression scale, MMSE = minimental state examination, NPI = Neuropsychiatric Index, SPGL = Spore Powder of Ganoderma Lucidum, WHOQOL-BREF = World Health Organization Quality of Life questionnaire.</p></fn><fn fn-type="supported-by"><p>This study was supported by the Dr. Start Project of Jiamusi University (22Zb201510).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Impaired retinal microcirculation in patients with Alzheimer's disease</article-title>. <source>PLoS One</source>
<year>2018</year>;<volume>13</volume>:<fpage>e0192154</fpage>.<pub-id pub-id-type="pmid">29394263</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjichrysanthou</surname><given-names>C</given-names></name><name><surname>Ower</surname><given-names>AK</given-names></name><name><surname>de Wolf</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>The development of a stochastic mathematical model of Alzheimer's disease to help improve the design of clinical trials of potential treatments</article-title>. <source>PLoS One</source>
<year>2018</year>;<volume>13</volume>:<fpage>e0190615</fpage>.<pub-id pub-id-type="pmid">29377891</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>XJ</given-names></name><etal/></person-group>
<article-title>Therapeutic efficacy of neuromuscular electrical stimulation and electromyographic biofeedback on Alzheimer's disease patients with dysphagia</article-title>. <source>Medicine (Baltimore)</source>
<year>2017</year>;<volume>96</volume>:<fpage>e8008</fpage>.<pub-id pub-id-type="pmid">28885365</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Xing</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Towards Personalized Intervention for Alzheimer's Disease</article-title>. <source>Genomics Proteomics Bioinformatics</source>
<year>2016</year>;<volume>14</volume>:<fpage>289</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">27693548</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>CA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name></person-group>
<article-title>Alzheimer's disease</article-title>. <source>Eur J Neurol</source>
<year>2018</year>;<volume>25</volume>:<fpage>59</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28872215</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jindal</surname><given-names>H</given-names></name><name><surname>Bhatt</surname><given-names>B</given-names></name><name><surname>Sk</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Alzheimer disease immunotherapeutics: then and now</article-title>. <source>Hum Vaccin Immunother</source>
<year>2014</year>;<volume>10</volume>:<fpage>2741</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">25483498</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brookmeyer</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Ziegler-Graham</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Forecasting the global burden of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>
<year>2007</year>;<volume>3</volume>:<fpage>186</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">19595937</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name></person-group>
<article-title>Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers</article-title>. <source>Biochem Pharmacol</source>
<year>2014</year>;<volume>88</volume>:<fpage>640</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24398425</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Effects of donepezil on cognitive functions and the expression level of &#x003b2;-amyloid in peripheral blood of patients with Alzheimer's disease</article-title>. <source>Exp Ther Med</source>
<year>2018</year>;<volume>15</volume>:<fpage>1875</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29434777</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batarseh</surname><given-names>YS</given-names></name><name><surname>Kaddoumi</surname><given-names>A</given-names></name></person-group>
<article-title>Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-&#x003b2; load and related toxicity in a mouse model of Alzheimer's disease</article-title>. <source>J Nutr Biochem</source>
<year>2017</year>;<volume>55</volume>:<fpage>113</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">29413486</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>CJD</given-names></name><name><surname>Hwang</surname><given-names>YT</given-names></name><name><surname>Bond</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Donepezil enhances understanding of degraded speech in Alzheimer's disease</article-title>. <source>Ann Clin Transl Neurol</source>
<year>2017</year>;<volume>4</volume>:<fpage>835</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29159197</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Park</surname><given-names>SU</given-names></name></person-group>
<article-title>Pharmacological aspects of galantamine for the treatment of Alzheimer's disease</article-title>. <source>EXCLI J</source>
<year>2017</year>;<volume>16</volume>:<fpage>35</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28337117</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokuchi</surname><given-names>R</given-names></name><name><surname>Hishikawa</surname><given-names>N</given-names></name><name><surname>Matsuzono</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease</article-title>. <source>Geriatr Gerontol Int</source>
<year>2016</year>;<volume>16</volume>:<fpage>440</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25952367</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Matsunaga</surname><given-names>S</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name></person-group>
<article-title>The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis</article-title>. <source>Neuropsychiatr Dis Treat</source>
<year>2017</year>;<volume>13</volume>:<fpage>1909</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">28790827</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Matsunaga</surname><given-names>S</given-names></name><name><surname>Oya</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Memantine for Alzheimer's disease: an updated systematic review and meta-analysis</article-title>. <source>J Alzheimers Dis</source>
<year>2017</year>;<volume>60</volume>:<fpage>401</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">28922160</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Efficacy of tenuigenin and &#x003b2;-asarone as augmentations for memantine in the treatment of Alzheimer's disease</article-title>. <source>Neuroreport</source>
<year>2018</year>;<volume>29</volume>:<fpage>203</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29298173</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birks</surname><given-names>JS</given-names></name><name><surname>Grimley Evans</surname><given-names>J</given-names></name></person-group>
<article-title>Rivastigmine for Alzheimer's disease</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2015</year>;<fpage>CD001191</fpage>.</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Servello</surname><given-names>A</given-names></name><name><surname>Ettorre</surname><given-names>E</given-names></name><name><surname>Cacciafesta</surname><given-names>M</given-names></name></person-group>
<article-title>Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease</article-title>. <source>Panminerva Med</source>
<year>2017</year>;<volume>59</volume>:<fpage>275</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28665099</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Matamales</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Modes of A&#x003b2; toxicity in Alzheimer's disease</article-title>. <source>Cell Mol Life Sci</source>
<year>2011</year>;<volume>68</volume>:<fpage>3359</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">21706148</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drolle</surname><given-names>E</given-names></name><name><surname>Negoda</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Changes in lipid membranes may trigger amyloid toxicity in Alzheimer's disease</article-title>. <source>PLoS One</source>
<year>2017</year>;<volume>12</volume>:<fpage>e0182194</fpage>.<pub-id pub-id-type="pmid">28767712</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntsapi</surname><given-names>C</given-names></name><name><surname>Lumkwana</surname><given-names>D</given-names></name><name><surname>Swart</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>New insights into autophagy dysfunction related to amyloid beta toxicity and neuropathology in Alzheimer's disease</article-title>. <source>Int Rev Cell Mol Biol</source>
<year>2018</year>;<volume>336</volume>:<fpage>321</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">29413893</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>SQ</given-names></name><name><surname>Chen</surname><given-names>BS</given-names></name><etal/></person-group>
<article-title>Pathology of ganoderma lucidum in treating APP/PS-1 Alzheimer's disease transgenic mice model</article-title>. <source>Chin Acad Med Sci</source>
<year>2017</year>;<volume>39</volume>:<fpage>552</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YP</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Effects of Ganoderma lucidum polysaccharide peptide on &#x003b2;-amyloid protein and hyperphosphorylation of tau protein in Alzheimer's disease rats</article-title>. <source>Chin J Pract Diagn Treat</source>
<year>2015</year>;<volume>29</volume>:<fpage>862</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>SB</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Ganoderma lucidum polysaccharide on Alzheimer's disease in rats learning and memory and oxidative stress</article-title>. <source>Shaanxi Med J</source>
<year>2011</year>;<volume>40</volume>:<fpage>387</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>YF</given-names></name><name><surname>Yao</surname><given-names>CX</given-names></name></person-group>
<article-title>Effects of Ganoderma lucidum polysaccharides on synaptic and synaptophysin expression in the hippocampus of Alzheimer's disease model rats</article-title>. <source>Acta Metallurgica Sinica</source>
<year>2011</year>;<volume>17</volume>:<fpage>151</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Effects of Ganoderma lucidum polysaccharides on the expression of Caspase-3 and FasL in hippocampus of AD model rats</article-title>. <source>Chin J Histochem Cytochem</source>
<year>2008</year>;<volume>19</volume>:<fpage>484</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>YJ</given-names></name><name><surname>LI</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name></person-group>
<article-title>Effects of Ganoderma lucidum polysaccharides on learning and memory in rats with Alzheimer's disease and its relationship with apoptosis of hippocampal cells</article-title>. <source>Anality Tribune</source>
<year>2008</year>;<volume>44</volume>:<fpage>376</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>YJ</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>LN</given-names></name><etal/></person-group>
<article-title>Effects of Ganoderma lucidum polysaccharides on the histopathology and antioxidant capacity of hippocampus in Alzheimer's disease rats</article-title>. <source>J Anatomy</source>
<year>2006</year>;<volume>53</volume>:<fpage>509</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>YJ</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Wen</surname><given-names>SW</given-names></name><etal/></person-group>
<article-title>Ganoderma lucidum polysaccharide on A&#x003b2;25-35-induced Alzheimer's disease in rats brain tissue protection</article-title>. <source>Chin J Histochem Cytochem</source>
<year>2006</year>;<volume>17</volume>:<fpage>447</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease</article-title>. <source>Neurology</source>
<year>1984</year>;<volume>34</volume>:<fpage>939</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double blind, placebo-controlled trial</article-title>. <source>Curr Alzheimer Res</source>
<year>2008</year>;<volume>5</volume>:<fpage>83</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18288936</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleck</surname><given-names>MPA</given-names></name></person-group>
<article-title>Desenvolvimento da vers&#x000e3;o em portugu&#x000ea;s do instrumento de avalia&#x000e7;&#x000e3;o de qualidade de vida da OMS (WHOQOL-100)</article-title>. <source>Rev Bras Psiquiatr</source>
<year>1999</year>;<volume>21</volume>:<fpage>19</fpage>&#x02013;<lpage>28</lpage>.</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title>. <source>Neurology</source>
<year>1994</year>;<volume>44</volume>:<fpage>2308</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">7991117</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johanson</surname><given-names>GA</given-names></name><name><surname>Brooks</surname><given-names>GP</given-names></name></person-group>
<article-title>Initial scale development: sample size for pilot studies</article-title>. <source>Educ Psychol Meas</source>
<year>2010</year>;<volume>70</volume>:<fpage>394</fpage>&#x02013;<lpage>400</lpage>.</mixed-citation></ref></ref-list></back></article>